Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33524-5. doi: 10.1016/j.jtho.2019.09.196. [Epub ahead of print]

PMID:
31605799
2.

Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.

El Amrani M, Corfiotti F, Corvaisier M, Vasseur R, Fulbert M, Skrzypczyk C, Deshorgues AC, Gnemmi V, Tulasne D, Lahdaoui F, Vincent A, Pruvot FR, Van Seuningen I, Huet G, Truant S.

Mol Carcinog. 2019 Nov;58(11):1985-1997. doi: 10.1002/mc.23090. Epub 2019 Aug 2.

PMID:
31373074
3.

Plasmodium pseudo-Tyrosine Kinase-like binds PP1 and SERA5 and is exported to host erythrocytes.

Gnangnon B, Fréville A, Cailliau K, Leroy C, De Witte C, Tulasne D, Martoriarti A, Jung V, Guerrera IC, Marion S, Khalife J, Pierrot C.

Sci Rep. 2019 May 31;9(1):8120. doi: 10.1038/s41598-019-44542-3.

4.

Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.

Duplaquet L, Figeac M, Leprêtre F, Frandemiche C, Villenet C, Sebda S, Sarafan-Vasseur N, Bénozène M, Vinchent A, Goormachtigh G, Wicquart L, Rousseau N, Beaussire L, Truant S, Michel P, Sabourin JC, Galateau-Sallé F, Copin MC, Zalcman G, De Launoit Y, Fafeur V, Tulasne D.

Mol Cancer Ther. 2019 Jun;18(6):1137-1148. doi: 10.1158/1535-7163.MCT-18-0582. Epub 2019 Mar 29.

PMID:
30926633
5.

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase.

Fernandes M, Duplaquet L, Tulasne D.

BMB Rep. 2019 Apr;52(4):239-249. Review.

6.

MET amplification increases the metastatic spread of EGFR-mutated NSCLC.

Baldacci S, Kherrouche Z, Cockenpot V, Stoven L, Copin MC, Werkmeister E, Marchand N, Kyheng M, Tulasne D, Cortot AB.

Lung Cancer. 2018 Nov;125:57-67. doi: 10.1016/j.lungcan.2018.09.008. Epub 2018 Sep 11.

PMID:
30429039
7.

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.

Descarpentries C, Leprêtre F, Escande F, Kherrouche Z, Figeac M, Sebda S, Baldacci S, Grégoire V, Jamme P, Copin MC, Tulasne D, Cortot AB.

J Thorac Oncol. 2018 Dec;13(12):1873-1883. doi: 10.1016/j.jtho.2018.08.2023. Epub 2018 Sep 7.

PMID:
30195702
8.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, Tulasne D, Cortot AB.

Rev Mal Respir. 2018 Oct;35(8):796-812. doi: 10.1016/j.rmr.2018.01.011. Epub 2018 Aug 31. Review. French.

PMID:
30174236
9.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

10.

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors.

Mekki MS, Mougel A, Vinchent A, Paquet C, Copin MC, Leroy C, Kherrouche Z, Bonte JP, Melnyk O, Vicogne J, Tulasne D.

Oncotarget. 2018 Jun 5;9(43):27039-27058. doi: 10.18632/oncotarget.25472. eCollection 2018 Jun 5.

11.

The multiple paths towards MET receptor addiction in cancer.

Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, Tulasne D.

Oncogene. 2018 Jun;37(24):3200-3215. doi: 10.1038/s41388-018-0185-4. Epub 2018 Mar 19. Review.

PMID:
29551767
12.

Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection.

Hasna J, Hague F, Rodat-Despoix L, Geerts D, Leroy C, Tulasne D, Ouadid-Ahidouch H, Kischel P.

Cell Death Differ. 2018 Mar;25(4):693-707. doi: 10.1038/s41418-017-0007-1. Epub 2018 Jan 11.

13.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

14.

Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases.

Benhabiles H, Gonzalez-Hilarion S, Amand S, Bailly C, Prévotat A, Reix P, Hubert D, Adriaenssens E, Rebuffat S, Tulasne D, Lejeune F.

PLoS One. 2017 Nov 13;12(11):e0187930. doi: 10.1371/journal.pone.0187930. eCollection 2017.

15.

Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins.

Jia J, Werkmeister E, Gonzalez-Hilarion S, Leroy C, Gruenert DC, Lafont F, Tulasne D, Lejeune F.

J Cell Sci. 2017 Sep 15;130(18):3009-3022. doi: 10.1242/jcs.198176. Epub 2017 Jul 25.

16.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. Review.

PMID:
28376232
17.

Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.

Lapère C, Cortot AB, Grégoire V, Cockenpot V, Tulasne D, Copin MC.

Am J Surg Pathol. 2017 Mar;41(3):414-422. doi: 10.1097/PAS.0000000000000810.

PMID:
28098570
18.

MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.

Montagne R, Baranzelli A, Muharram G, Catherine L, Lesaffre M, Vinchent A, Kherrouche Z, Werkmeister E, Cortot AB, Tulasne D.

Oncotarget. 2017 Feb 14;8(7):11268-11283. doi: 10.18632/oncotarget.14499.

19.

[MET receptor inhibition: Hope against resistance to targeted therapies?]

Hochart A, Leblond P, Le Bourhis X, Meignan S, Tulasne D.

Bull Cancer. 2017 Feb;104(2):157-166. doi: 10.1016/j.bulcan.2016.10.014. Epub 2016 Nov 15. Review. French.

PMID:
27863726
20.

High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.

Copin MC, Lesaffre M, Berbon M, Doublet L, Leroy C, Tresch E, Porte H, Vicogne J, B Cortot A, Dansin E, Tulasne D.

Lung Cancer. 2016 Nov;101:59-67. doi: 10.1016/j.lungcan.2016.09.009. Epub 2016 Sep 14.

PMID:
27794409
21.

The caspase-generated cleavage product of Ets-1 p51 and Ets-1 p27, Cp17, induces apoptosis.

Choul-Li S, Tulasne D, Aumercier M.

Biochem Biophys Res Commun. 2016 Nov 4;480(1):1-7. doi: 10.1016/j.bbrc.2016.10.020. Epub 2016 Oct 11.

PMID:
27737766
22.

ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease.

Letronne F, Laumet G, Ayral AM, Chapuis J, Demiautte F, Laga M, Vandenberghe ME, Malmanche N, Leroux F, Eysert F, Sottejeau Y, Chami L, Flaig A, Bauer C, Dourlen P, Lesaffre M, Delay C, Huot L, Dumont J, Werkmeister E, Lafont F, Mendes T, Hansmannel F, Dermaut B, Deprez B, Hérard AS, Dhenain M, Souedet N, Pasquier F, Tulasne D, Berr C, Hauw JJ, Lemoine Y, Amouyel P, Mann D, Déprez R, Checler F, Hot D, Delzescaux T, Gevaert K, Lambert JC.

EBioMedicine. 2016 Jul;9:278-292. doi: 10.1016/j.ebiom.2016.06.002. Epub 2016 Jun 2.

23.

Caspase Cleavages of the Lymphocyte-oriented Kinase Prevent Ezrin, Radixin, and Moesin Phosphorylation during Apoptosis.

Leroy C, Belkina NV, Long T, Deruy E, Dissous C, Shaw S, Tulasne D.

J Biol Chem. 2016 May 6;291(19):10148-61. doi: 10.1074/jbc.M116.721365. Epub 2016 Mar 4.

24.

PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Kherrouche Z, Monte D, Werkmeister E, Stoven L, De Launoit Y, Cortot AB, Tulasne D, Chotteau-Lelievre A.

Mol Oncol. 2015 Nov;9(9):1852-67. doi: 10.1016/j.molonc.2015.07.001. Epub 2015 Jul 15.

25.

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences.

Montagne R, Berbon M, Doublet L, Debreuck N, Baranzelli A, Drobecq H, Leroy C, Delhem N, Porte H, Copin MC, Dansin E, Furlan A, Tulasne D.

Cell Death Dis. 2015 May 21;6:e1769. doi: 10.1038/cddis.2015.132.

26.

Caspases shutdown nonsense-mediated mRNA decay during apoptosis.

Jia J, Furlan A, Gonzalez-Hilarion S, Leroy C, Gruenert DC, Tulasne D, Lejeune F.

Cell Death Differ. 2015 Nov;22(11):1754-63. doi: 10.1038/cdd.2015.18. Epub 2015 Mar 6.

27.

Semi-synthesis of a HGF/SF kringle one (K1) domain scaffold generates a potent in vivo MET receptor agonist.

Simonneau C, Bérénice Leclercq, Mougel A, Adriaenssens E, Paquet C, Raibaut L, Ollivier N, Drobecq H, Marcoux J, Cianférani S, Tulasne D, de Jonge H, Melnyk O, Vicogne J.

Chem Sci. 2015 Mar 1;6(3):2110-2121. doi: 10.1039/c4sc03856h. Epub 2015 Jan 29.

28.

Thirty years of research on met receptor to move a biomarker from bench to bedside.

Furlan A, Kherrouche Z, Montagne R, Copin MC, Tulasne D.

Cancer Res. 2014 Dec 1;74(23):6737-44. doi: 10.1158/0008-5472.CAN-14-1932. Epub 2014 Nov 19. Review.

29.

[Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies].

Montagne R, Furlan A, Kherrouche Z, Tulasne D.

Med Sci (Paris). 2014 Oct;30(10):864-73. doi: 10.1051/medsci/20143010013. Epub 2014 Oct 14. Review. French.

30.

Tensin-4-Dependent MET Stabilization Is Essential for Survival and Proliferation in Carcinoma Cells.

Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, Tulasne D, Carpén O, Ivaska J.

Dev Cell. 2014 Jun 9;29(5):629-630. doi: 10.1016/j.devcel.2014.05.018. Epub 2014 Jun 9. No abstract available.

31.

Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.

Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, Tulasne D, Carpén O, Ivaska J.

Dev Cell. 2014 May 27;29(4):421-36. doi: 10.1016/j.devcel.2014.03.024. Epub 2014 May 8. Erratum in: Dev Cell. 2014 Jun 9:29(5):629-30.

32.

How does met regulate the survival/apoptosis balance?

Furlan A, Tulasne D.

Hepatology. 2014 Sep;60(3):1108-9. doi: 10.1002/hep.26969. Epub 2014 Jul 28. No abstract available.

PMID:
24347525
33.

Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity.

Lefebvre J, Muharram G, Leroy C, Kherrouche Z, Montagne R, Ichim G, Tauszig-Delamasure S, Chotteau-Lelievre A, Brenner C, Mehlen P, Tulasne D.

Cell Death Dis. 2013 Oct 17;4:e871. doi: 10.1038/cddis.2013.377.

34.

The dependence receptor TrkC triggers mitochondria-dependent apoptosis upon Cobra-1 recruitment.

Ichim G, Genevois AL, Ménard M, Yu LY, Coelho-Aguiar JM, Llambi F, Jarrosson-Wuilleme L, Lefebvre J, Tulasne D, Dupin E, Le Douarin N, Arumäe U, Tauszig-Delamasure S, Mehlen P.

Mol Cell. 2013 Sep 12;51(5):632-46. doi: 10.1016/j.molcel.2013.08.021.

35.

Loss of a negative feedback loop involving pea3 and cyclin d2 is required for pea3-induced migration in transformed mammary epithelial cells.

Ladam F, Damour I, Dumont P, Kherrouche Z, de Launoit Y, Tulasne D, Chotteau-Lelievre A.

Mol Cancer Res. 2013 Nov;11(11):1412-24. doi: 10.1158/1541-7786.MCR-13-0229. Epub 2013 Aug 29.

36.

Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway.

Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A, Kherrouche Z, Foveau B, Pourtier A, Melnyk O, Giordano S, Chotteau-Lelievre A, Tulasne D.

Traffic. 2012 Sep;13(9):1261-72. doi: 10.1111/j.1600-0854.2012.01384.x. Epub 2012 Jun 20.

37.

Caspase cleavage of viral proteins, another way for viruses to make the best of apoptosis.

Richard A, Tulasne D.

Cell Death Dis. 2012 Mar 8;3:e277. doi: 10.1038/cddis.2012.18. Review.

38.

The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase.

Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, Guérardel Y, Le Bourhis X, Tulasne D, Delannoy P.

Glycobiology. 2012 Jun;22(6):806-16. doi: 10.1093/glycob/cws049. Epub 2012 Feb 1.

PMID:
22301273
39.

Met degradation: more than one stone to shoot a receptor down.

Lefebvre J, Ancot F, Leroy C, Muharram G, Lemière A, Tulasne D.

FASEB J. 2012 Apr;26(4):1387-99. doi: 10.1096/fj.11-197723. Epub 2012 Jan 5. Review.

PMID:
22223753
40.

Preparation and characterization of Zonyl-coated nanodiamonds with antifouling properties.

Marcon L, Kherrouche Z, Lyskawa J, Fournier D, Tulasne D, Woisel P, Boukherroub R.

Chem Commun (Camb). 2011 May 14;47(18):5178-80. doi: 10.1039/c1cc10338e. Epub 2011 Mar 14.

PMID:
21399833
41.

GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation.

Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delannoy P.

Mol Cancer Res. 2010 Nov;8(11):1526-35. doi: 10.1158/1541-7786.MCR-10-0302. Epub 2010 Oct 1.

42.

Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function.

Choul-Li S, Leroy C, Leprivier G, Laitem C, Tulasne D, Aumercier M.

Biochem J. 2010 Feb 9;426(2):229-41. doi: 10.1042/BJ20090877.

PMID:
20001963
43.

Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage.

Deheuninck J, Goormachtigh G, Foveau B, Ji Z, Leroy C, Ancot F, Villeret V, Tulasne D, Fafeur V.

Cell Signal. 2009 Sep;21(9):1455-63. doi: 10.1016/j.cellsig.2009.05.005. Epub 2009 May 18.

PMID:
19450681
44.

Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity.

Ancot F, Foveau B, Lefebvre J, Leroy C, Tulasne D.

Oncogene. 2009 Jun 4;28(22):2185-95. doi: 10.1038/onc.2009.88. Review. No abstract available.

PMID:
19421148
45.

Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D.

Mol Biol Cell. 2009 May;20(9):2495-507. doi: 10.1091/mbc.E08-09-0969. Epub 2009 Mar 18.

46.

Caspase cleavage of the MET receptor generates an HGF interfering fragment.

Deheuninck J, Foveau B, Goormachtigh G, Leroy C, Ji Z, Tulasne D, Fafeur V.

Biochem Biophys Res Commun. 2008 Mar 14;367(3):573-7. doi: 10.1016/j.bbrc.2007.12.177. Epub 2008 Jan 8.

PMID:
18187039
47.

The shadow of death on the MET tyrosine kinase receptor.

Tulasne D, Foveau B.

Cell Death Differ. 2008 Mar;15(3):427-34. Epub 2007 Oct 5. Review.

48.

Molecular cloning and characterisation of SmSLK, a novel Ste20-like kinase in Schistosoma mansoni.

Yan Y, Tulasne D, Browaeys E, Cailliau K, Khayath N, Pierce RJ, Trolet J, Fafeur V, Ben Younes A, Dissous C.

Int J Parasitol. 2007 Dec;37(14):1539-50. Epub 2007 Jun 21.

PMID:
17651740
49.

HGF/SF regulates expression of apoptotic genes in MCF-10A human mammary epithelial cells.

Leroy C, Deheuninck J, Reveneau S, Foveau B, Ji Z, Villenet C, Quief S, Tulasne D, Kerckaert JP, Fafeur V.

Ann N Y Acad Sci. 2006 Dec;1090:188-202.

PMID:
17384262
50.

Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor.

Foveau B, Leroy C, Ancot F, Deheuninck J, Ji Z, Fafeur V, Tulasne D.

Cell Death Differ. 2007 Apr;14(4):752-64. Epub 2006 Dec 22.

Supplemental Content

Loading ...
Support Center